Status:
COMPLETED
Neurocognitive Impairment in Patients With COVID-19
Lead Sponsor:
University of Rostock
Collaborating Sponsors:
Ludwig-Maximilians - University of Munich
University College, London
Conditions:
Critical Illness
COVID-19
Eligibility:
All Genders
Brief Summary
Delirium and acute neurocognitive impairment are increasingly observed in adult and pediatric patients with COVID-19. Prospective clinical studies combining clinical and laboratory examinations includ...
Detailed Description
This is a multicenter observational study evaluating the incidence and severity of neurocognitive impairment in adult and pediatric patients with COVID-19. All study participants will be assessed by c...
Eligibility Criteria
Inclusion
- adult patients of every age
- admission to hospital with suspected COVID-19 disease
- confirmed SARS-CoV-2 infection within 48 hours after admission
Exclusion
- transferral from another hospital
- other acute central nervous system diseases (e.g. meningoencephalitis, intracerebral ischemia or hemorrhage)
- confirmed SARS-CoV-2 infection later than 48 hours after hospital admission
- participation in another interventional study
- no written informed consent from patient or legal representative
Key Trial Info
Start Date :
April 15 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 31 2023
Estimated Enrollment :
118 Patients enrolled
Trial Details
Trial ID
NCT04359914
Start Date
April 15 2020
End Date
December 31 2023
Last Update
January 29 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Anesthesiology and Intensive Care Medicine, University Medical Center Rostock
Rostock, Mecklenburg-Vorpommern, Germany, D-18057